Scalper1 News
Biotech Acorda Therapeutics (ACOR) said Monday that it had reached a settlement with Actavis, the generic-drug arm of Allergan (AGN), agreeing that Actavis’ generic version of Acorda’s drug Ampyra won’t come out until 2027. Acorda stock rose sharply while Allergan’s fell. The news, which was revealed only through a terse SEC filing, came as a big surprise to Wall Street. Most had expected the generic version of Acorda’s multiple-sclerosis drug to Scalper1 News
Scalper1 News